fused compound containing fleroxacin combined with desacetylcefotaxime; active against gram-positive bacteria
Also Known As:
Ro 23-9424
Networked: 5 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1. Infection
04/01/1992 - "The MIC for 90% of isolates (MIC90) of Pseudomonas aeruginosa was 16.0 micrograms/ml. All group A and B streptococci were inhibited by less than or equal to 0.25 micrograms/ml, and 90% of group G streptococci and Streptococcus pneumoniae were inhibited by 1.0 micrograms/ml. All methicillin-susceptible strains of Staphylococcus aureus and 60% of methicillin-resistant strains were susceptible to 2.0 micrograms of Ro 23-9424 per ml, whereas the MIC90 for Staphylococcus epidermidis and Staphylococcus hominis isolates was 4.0 micrograms/ml. Staphylococcus haemolyticus and Enterococcus spp. were less susceptible; MIC90s for them were 16.0 and 32.0 micrograms/ml. Ro 23-9424 has a broad antibacterial spectrum and potential utility for therapy of infections in cancer patients."
01/01/1990 - "In the control normal (immunocompetent) mouse infection, Ro 23-9424 was 3-fold more active than cefotaxime, but 10-fold less active than fleroxacin."
01/01/1990 - "Ro 23-9424 demonstrated significant activity against all strains tested in systemic infections, including those strains resistant in vivo to cefotaxime (Staphylococcus aureus 753, Serratia marcescens SM and Pseudomonas aeruginosa 8780) and fleroxacin (Streptococcus pneumoniae 6301 and Streptococcus pyogenes. "
03/01/1989 - "A novel fused co-drug of fleroxacin and desacetyl-cefotaxime, Ro 23-9424, was 100% effective against these Gram-positive pathogens at less than or equal to 8 micrograms/ml. Several of these compounds should receive consideration for clinical trials for empiric therapy among neutropenic patient infections where Gram-positive pathogens may be more prevalent."
2. Pneumonia (Pneumonitis)
3. Neoplasms (Cancer)
4. Necrosis
5. Body Weight (Weight, Body)

Related Drugs and Biologics

1. Fleroxacin
2. Cefotaxime (Kendrick)
3. Carbon Monoxide
4. Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
5. Methicillin (Metin)
6. Ciprofloxacin (Cipro)
7. Ceftazidime (Fortum)
8. Cefoperazone (Cefoperazone Sodium)